To explore the potential clinical relevance of our initial observations, we determined transcript levels of both MAP3K8 and its binding partner NFKB1 in CML CD34+ cells exposed to IM. This evidence concerns the gene MAP3K8 and chronic myelogenous leukemia, BCR-ABL1 positive.